# Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110

> **NCT00631878** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biosynexus Incorporated** · enrollment: 53 (actual)

## Conditions studied

- Neonatal Staphylococcal Sepsis

## Interventions

- **DRUG:** Pagibaximab (formerly BSYX-A110)

## Key facts

- **NCT ID:** NCT00631878
- **Lead sponsor:** Biosynexus Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2003-05
- **Final completion:** 2003-08
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2008-03-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00631878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00631878, "Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00631878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*